Screening and vaccine: Toward an integrated cervical cancer prevention programme;Screening e vaccini: Verso un programma integrato di prevenzione del cervicocarcinoma

Epidemiologia e Prevenzione

Volumn 32, Issue 4-5, 2008, Pages 238-243

  Rossi, Paolo Giorgi ^a   Ronco, Guglielmo ^b   Segnan, Nereo ^b   Borgia, Piero ^a  

^a Agenzia di Sanita Pubblica   (Italy)

^b CPO Piemonte   (Italy)

Author keywords

Cervical cancer; Human papilloma virus (HPV); Screening; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; FEMALE; HUMAN; ITALY; MASS SCREENING; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

FEMALE; HUMANS; ITALY; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 63049131862     PISSN: 11209763     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. LEA; Decreto del Presidente del Consiglio dei Ministri del 29 novembre 2001.
2. ISTAT - Statistiche in breve. Sanità. La prevenzione dei tumori femminili in Italia: il ricorso a Pap test e mammografìa. Anni 2004-2005. ISTAT, Roma, 2006.
3. Ministero della Salute - Direzione Generale della Prevenzione. Raccomandazioni per la pianificazione e l'esecuzione degli screening di popolazione per la prevenzione del cancro della mammella, del cancro della cervice uterina e del cancro del colon retto. Ministero della Salute, Roma 2005. hnp://www.osservatorionazionalescreening.it/ons/documentazione/raccomandazioni/ screening-vers-completa.pdf.
4. Ronco G, Cuzick J, Segnan N et al.; NTCC Working Group. HPV triage for Low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer 2007;43(3):476-80.
5. Bulkmans NW, Berkhof J, Rozendaal L et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer:5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370(9601):1764-72.
6. Naucler P, Ryd W, Tornberg S et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357(16):1589-97.
7. Ronco G, Giorgi Rossi P, Carozzi F et al. and the NTCC Working Group. Human papillomavirus testing and liquid-based cytology in primary screening among younger women: results at recruitment from the NTCC randomised controlled trial. Lancet Oncol 2006;7(7):547-55.
8. Ronco G, Segnan N. HPV testing for primary cervical cancer screening (invited comment). Lancet 2007;370(9601):1740-42
9. Ronco G, Giorgi Rossi P, Carozzi F et al.; NTCC Working Group. Results at Recruitment from a Randomized Controlled Trial Comparing Human Papillomavirus Testing Alone to Conventional Cytology as the Primary Cervical Cancer Screening Test. J Natl Cancer Inst 2008;100(7):492-501.
10. Dalla Palma P, Giorgi Rossi P, Collina G et al.; NTCC Pathology Group. The risk of false-positive histology according to the reason for colposcopy referral in cervical cancer screening: a blind revision of all histological lesions found in the NTCC trial. Am J Clin Pathol 2008;129(1):75-80
11. Kotaniemi-Talonen L, Anttila A, Malila N et al. Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer 2008;44(4):565-71.
12. Ronco G, Segnan N, Giorgi Rossi P et al.; NTCC Working Group. Human Papillomavirus testing and liquid-based cytology in primary cervical screening: results at recruitment from the NTCC randomized controlled trial. J Natl Cancer Inst 2006;98(11):765-74.
13. Giorgi Rossi P, Segnan N, Zappa M et al.; NTCC Working Group. The impact of new technologies in cervical cancer screening: results of the recruitment phase of a large randomised controlled trial from a public health perspective. Int J Cancer 2007;121(12):2729-34.
14. Bosch FX, Castellsagué X, De Sanjosé S. HPV and cervical cancer: screening or vaccination? Br J Cancer 2008;98(1):15-21.
15. Kiviat NB, Hawes SE, Feng Q. Screening for cervical cancer in the era of the HPV vaccine - the urgent need for both new screening guidelines and new biomarkers. J Natl Cancer Inst 2008;100(5):290-91.
16. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370(9590):890-907.
17. IARC Handbooks of Cancer Prevention Vol. 10 Cervix Cancer Screening. IARC, Lion, 2005
18. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24(Suppl 3):S26-34.
19. Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J. Chapter 10: New dimensions in cervical cancer screening. Vaccine 2006;24(Suppl 3):S90-97.
20. Franco EL, Cuzick J, Hildesheim A, De Sanjosé S. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006;24(Suppl 3):S171-77.
21. Meijer CJ, Berkhof J, Heideman DA, Snijeder PJ. Cercival cancer prevention. Who should have vaccination? Nature Clin Pract Oncol 2008;5(1):12-13.
22. Jeronimo J, Massad LS, Schiffman M; National Institutes of Health/American Society for Colposcopy and Cervical Pathology (NIH/ASCCP) Research Group. Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type. Am J Obstet Gynecol 2007;197():47.e1-8.
23. Khan MJ, Castle PE, Lorincz AT et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;970:1072-79.
24. Winer RL, Kiviat NB, Hughes JP et al. Development and duration of human papillomavirus lesions after initial infection. J Infect Dis 2005;1910:731-38.
25. Castellsagué X, Diaz M, De Sanjosé S et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;98():303-15.
26. Ronco G, Pilutti S, Patriarca S, et al. Turin Cervical Screening Working Group. Impact of the introduction of organised screening for cervical cancer in Turin, Italy: cancer incidence by screening history 1992-98. Br J Cancer 2005;930:376-78.
27. National Institute for Health and Clinical Excellence, www.nice.org.uk
28. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16, 18 vaccination. J Natl Cancer Inst 2008;100():308-20.